Asset Details
Do you wish to reserve the book?
SLC1A5 enhances malignant phenotypes through modulating ferroptosis status and immune microenvironment in glioma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
SLC1A5 enhances malignant phenotypes through modulating ferroptosis status and immune microenvironment in glioma
Do you wish to request the book?
SLC1A5 enhances malignant phenotypes through modulating ferroptosis status and immune microenvironment in glioma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
SLC1A5 enhances malignant phenotypes through modulating ferroptosis status and immune microenvironment in glioma
2022
Overview
Glioma is the most common type of primary malignant tumor in the central nervous system with limited treatment satisfaction. Finding new therapeutic targets has remained a major challenge. Ferroptosis is a novel and distinct type of programmed cell death, playing a regulatory role in the progression of tumors. However, the role of ferroptosis or ferroptosis-related genes (FRGs) in glioma progression has not been extensively studied. In our study, a novel ferroptosis-related prognostic model, including 7 genes, was established, in which patients classified into the high-risk group had more immuno-suppressive status and worse prognosis. Among these 7 genes, we screened solute carrier family 1 member 5 (SLC1A5), an FRG, as a possible new target for glioma treatment. Our results showed that the expression of SLC1A5 was significantly upregulated in glioblastoma tissues compared with the low-grade gliomas. In addition, SLC1A5 knockdown could significantly inhibit glioma cell proliferation and invasion, and reduce the sensitivity of ferroptosis via the GPX4-dependent pathway. Furthermore, SLC1A5 was found to be related to immune response and SLC1A5 knockdown decreased the infiltration and M2 polarization of tumor-associated macrophages. Pharmacological inhibition of SLC1A5 by V9302 was confirmed to promote the efficacy of anti-PD-1 therapy. Overall, we developed a novel prognostic model for glioma based on the seven-FRGs signature, which could apply to glioma prognostic and immune status prediction. Besides, SLC1A5 in the model could regulate the proliferation, invasion, ferroptosis and immune state in glioma, and be applied as a prognostic biomarker and potential therapeutic target for glioma.
Publisher
Nature Publishing Group UK,Springer Nature B.V,Nature Publishing Group
Subject
/ 13/109
/ 13/31
/ 13/51
/ 38/5
/ 38/77
/ 38/91
/ 82/29
/ 82/51
/ 82/58
/ Amino Acid Transport System ASC - genetics
/ Amino Acid Transport System ASC - physiology
/ Biomedical and Life Sciences
/ Brain Neoplasms - immunology
/ Genes
/ Glioma
/ Humans
/ Minor Histocompatibility Antigens - genetics
/ Minor Histocompatibility Antigens - physiology
/ Proteins
